SELLAS investors back directors and equity plan
SELLAS Life Sciences Group, Inc. reported the results of its Annual Meeting of Stockholders held on June 16, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
SELLAS Life Sciences Group, Inc. reported the results of its Annual Meeting of Stockholders held on June 16, 2026. A total of 115,511,771 shares, representing approximately 62.59% of outstanding common stock, were present in person or by proxy, establishing a valid quorum.
Stockholders re-elected Class I directors Robert Van Nostrand and Jane Wasman to serve until the 2029 Annual Meeting, ratified Baker Tilly US, LLP as independent auditor for the year ending December 31, 2026, and approved an amendment to the 2023 Equity Incentive Plan to add 20,000,000 shares. They also approved the advisory vote on executive compensation and an adjournment proposal to solicit additional proxies if needed.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares represented at meeting: 115,511,771 shares
Meeting participation rate: 62.59%
Equity plan share increase: 20,000,000 shares
+3 more
6 metrics
Shares represented at meeting
115,511,771 shares
Approximately 62.59% of outstanding common stock at June 16, 2026 Annual Meeting
Meeting participation rate
62.59%
Percentage of all outstanding shares present or represented by proxy at Annual Meeting
Equity plan share increase
20,000,000 shares
Additional common shares available under 2023 Amended and Restated Equity Incentive Plan
Auditor ratification - For votes
112,103,701 votes
Votes for ratifying Baker Tilly US, LLP as 2026 independent registered public accounting firm
Say-on-pay - For votes
52,930,792 votes
Support for advisory resolution on executive compensation of named executive officers
Adjournment proposal - For votes
90,571,992 votes
Approval to adjourn Annual Meeting if necessary to solicit additional proxies
Key Terms
Annual Meeting of Stockholders, broker non-votes, independent registered public accounting firm, Equity Incentive Plan, +1 more
5 terms
Annual Meeting of Stockholders financial
"On June 16, 2026, SELLAS Life Sciences Group, Inc. held its Annual Meeting of Stockholders"
broker non-votes financial
"FOR 42,906,271 AGAINST 27,310,386 ABSTAIN 817,521 BROKER NON-VOTES 44,477,593"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"ratified the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Equity Incentive Plan financial
"approved an amendment to the Company’s 2023 Amended and Restated Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
non-binding, advisory resolution financial
"approved the non-binding, advisory resolution on the executive compensation of the Company’s named executive officers"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did SELLAS Life Sciences (SLS) stockholders approve at the 2026 Annual Meeting?
Stockholders approved all five proposals, including director re-elections, auditor ratification, an equity plan share increase, advisory approval of executive compensation, and an adjournment proposal. These actions confirm governance decisions and provide additional equity capacity for future incentive awards.
Which directors were re-elected to the SELLAS (SLS) board in 2026?
Stockholders re-elected Robert Van Nostrand and Jane Wasman as Class I directors to serve until the 2029 Annual Meeting. Each received a majority of votes cast, with substantial broker non-votes reflecting shares not entitled to vote on the director proposals.
How did SELLAS (SLS) stockholders vote on the 2023 Equity Incentive Plan amendment?
Stockholders approved increasing shares available under the 2023 Equity Incentive Plan by 20,000,000. The vote was 42,906,271 for, 27,310,386 against, and 817,521 abstentions, with 44,477,593 broker non-votes, enabling the company to grant additional equity-based awards.
Which auditing firm did SELLAS (SLS) stockholders ratify for fiscal 2026?
Stockholders ratified Baker Tilly US, LLP, as successor to Moss Adams LLP, as independent registered public accounting firm for the year ending December 31, 2026. The ratification received 112,103,701 votes for, 2,126,460 against, and 1,281,610 abstentions, with no broker non-votes.
What was the outcome of SELLAS (SLS) say-on-pay vote in 2026?
Stockholders approved the non-binding advisory resolution on compensation for named executive officers. The result was 52,930,792 votes for, 15,906,732 against, and 2,196,654 abstentions, with 44,477,593 broker non-votes, indicating support for the disclosed executive pay program.
Did SELLAS (SLS) stockholders approve an adjournment option for the 2026 Annual Meeting?
Yes. Stockholders approved an adjournment proposal to allow the meeting to be adjourned, if necessary, to solicit additional proxies for the main proposals. The vote totaled 90,571,992 for, 22,200,030 against, and 2,739,749 abstentions, with no broker non-votes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
